NasdaqGM:LRMRBiotechs
Larimar Therapeutics (LRMR) Valuation After FDA Breakthrough Therapy Designation For Nomlabofusp
FDA milestones put Larimar Therapeutics (LRMR) and nomlabofusp in sharper focus
Larimar Therapeutics (LRMR) is back on investors’ radar after the FDA granted Breakthrough Therapy Designation to its Friedreich's ataxia candidate nomlabofusp and signaled openness to a surrogate endpoint supporting a potential accelerated approval filing.
See our latest analysis for Larimar Therapeutics.
The FDA update has arrived alongside a sharp pickup in momentum, with a 1 day share price return of 31.32%...